References
- Gass JDM. Stereoscopic atlas of macular diseases: diagnosis and treatment. 4th ed. St. Louis: Mosby Inc; 1997:52–70
- Bennet G. Central serous retinopathy. Br J Ophthalmol 1955;39:605–618
- Jalkh AE, Jabbour N, Avila MP, et al. Retinal pigment epithelium decompensation. I. Clinical features and natural course. Ophthalmology 1984;91:1544–1548
- Loo RH, Scott IU, Flynn HW, Jret al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002;22:19–24
- Wojtkowski M, Srinivasan V, Fujimoto JG, et al. Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 2005;112:1734–1746
- Hangai M, Ojima Y, Gotoh N, et al. Three dimensional imaging of macular holes with high speed optical coherence tomography. Ophthalmology 2007;114:763–773
- Ooto S, Hangai M, Sakamoto A, et al. Three dimensional profile of macular retinal thickness in normal Japanese eyes. Invest Ophthalmol Vis Sci 2010;51:465–473
- Koytak A, Erol K, Coskun E, et al. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina 2010;30:1698–1703
- Tarabishy AB, Ahn E, Mandell BF, Lowder CY. Central serous retinopathy. Arthritis Care Res (Hoboken) 2011;63:1075–1082
- Klein ML, Van Buskirk EM, Friedman E, et al. Experience with nontreatment of central serous choroidopathy. Arch Ophthalmol 1974;91:247–250
- Guyer DR, Gragoudas ES, Spaide RF, et al. Central serous chorioretinopathy. In: Albert DM, Jakobiec FA, eds. Principles and practice of ophthalmology. 2nd ed. Philadelphia: WB Saunders Company; 2000:1974–1982
- Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 2010;35:91–98
- Robertson DM, Ilstrup D. Direct, indirect, and shamlaser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 1983;95:457–466
- Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 2011;152:784–792
- Marcuson J, Riley T. Central serous chorioretinopathy. Optometry 2008;79:241–251
- Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye 2010;24:1743–1756
- Wang MS, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 2002;133:787–793
- Matsumoto H, Kishi S, Otani T, Sato T. Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 2008;145:162–168
- Matsumoto H, Sato T, Kishi S. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. Am J Ophthalmol 2009;148:105–110
- Piccolino FC, de la Longrais RR, Ravera G, et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol 2005;139:87–99
- Fujita K, Shinoda K, Imamura Y, et al. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy. Am J Ophthalmol 2012;154:579–585
- Ojima Y, Tsujikawa A, Yamashiro K, et al. Restoration of outer segments of foveal photoreceptors after resolution of central serous chorioretinopathy. Jpn J Ophthalmol 2010;54:55–60
- Seong HK, Bae JH, Kim ES, et al. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica 2009;223:343–347
- Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010;30:100–106
- Schaal KB, Hoeh AE, Scheuerle A, et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009;19:613–617
- Symeonidis C, Kaprinis K, Manthos K, et al. Central serous chorioretinopathy with subretinal deposition of fibrin-like material and its prompt response to ranibizumab injections. Case Report Ophthalmol 2011;2:59–64
- Saint-Geniez M, Maharaj ASR, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for survival role on Müller cells and photoreceptors. PLoS ONE 2008;3:e3554 (1--13)
- Avci B, Avci R, Inan ÜÜ, Kaderli B. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanip sodium in rabbits. Invest Ophthalmol Vis Sci 2009;50:3438–3446